In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 3, 2013, Pages 554-562

  Kuentz, Martin ^a   Imanidis, Georgios ^a,b  

^a UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Amorphous; Bioavailability; In silico; Molecular modeling; Oral drug absorption; Poorly soluble drugs

Indexed keywords

ALMITRINE; ALPRAZOLAM; AMPIROXICAM; ANASTROZOLE; BROTIZOLAM; BUDESONIDE; CALCITRIOL; CARBAMAZEPINE; CLOMETHIAZOLE; CLOZAPINE; DANAZOL; DESOGESTREL; DEXTROMORAMIDE; DIENOGEST; DOLASETRON MESILATE; ESTRADIOL; ESTRADIOL VALERATE; ETONOGESTREL; EXEMESTANE; FINASTERIDE; FLUNISOLIDE; FLUOCORTOLONE; FLUTICASONE; GLIBENCLAMIDE; GLIPIZIDE; GRISEOFULVIN; HYDROCHLOROTHIAZIDE; SPIRONOLACTONE; TERFENADINE; UNINDEXED DRUG; NEW DRUG;

ARTICLE; CHEMICAL STRUCTURE; COMPUTER MODEL; DRUG FORMULATION; DRUG SOLUBILITY; HYDROGEN BOND; MELTING POINT; MOLECULAR MODEL; MOLECULAR WEIGHT; PHARMACEUTICAL ENGINEERING; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SURFACE PROPERTY; BIOAVAILABILITY; BIOLOGICAL MODEL; BIOLOGY; CHEMICAL PHENOMENA; CHEMISTRY; CONFORMATION; DRUG DESIGN; DRUG DEVELOPMENT; EXPERT SYSTEM; HUMAN; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY; STATISTICAL MODEL; TRANSITION TEMPERATURE; VALIDATION STUDY;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; EXPERT SYSTEMS; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MODELS, STATISTICAL; MOLECULAR CONFORMATION; MOLECULAR WEIGHT; SOLUBILITY; SURFACE PROPERTIES; TRANSITION TEMPERATURE;

EID: 84872774511     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.11.015     Document Type: Article

References (38)

1. Alonzo, D.E., Gao, Y., Zhou, D., Mo, H., Zhang, G.G.Z., Taylor, L.S., 2011. Dissolution and precipitation behavior of amorphous solid dispersions. J. Pharm. Sci. 100 (8), 3316-3331.
2. Amidon, G., Lennernas, H., Shah, V., Crison, J., 1995. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (3), 413-420.
3. Aungst, B.J., 2000. Intestinal permeation enhancers. J. Pharm. Sci. 89 (4), 429-442.
4. Brewster, M.E., Vandecruys, R., Peeters, J., Neeskens, P., Verreck, G., Loftsson, T., 2008. Comparative interaction of a 2-hydroxy-b-cyclodextrin and sulfobutylether-b-cyclodextrin with itraconazole: Phase solubility behavior and stabilization of supersaturated drug solutions. Eur. J. Pharm. Sci. 34, 94-103.
5. Brouwers, J., Brewster, M.E., Augustijns, P., 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98 (8), 2549-2572.
6. Buttler, J.M., Dressman, J.B., 2010. The developability classification system: Application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 99 (12), 4940-4954.
7. Dai, W.G., Dong, L.C., Li, S., Deng, Z., 2008. Combination of Pluronic/Vitamin E TPGS as a potential inhibitor of drug precipitation. Int. J. Pharm. 355, 31-37.
8. Dannenfelser, R.M., Yalkowsky, S.H., 1996. Estimation of entropy of melting from molecular structure: A non-group contribution method. Ind. Eng. Chem. Res. 35 (4), 1483-1486.
9. Davies, M.E., Brewster, M., 2004. Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 3, 1023-1035.
10. Docherty, R., Meenan, P., 1999. The study of molecular materials using computational chemistry. In: Myerson, A.S. (Ed.), Molecular Modeling Applications in Crystallization. Cambridge University Press, Cambridge, New York, pp. 106-165.
11. Ert, P., Rohde, B., Selzer, P., 2000. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43 (20), 3714-3717.
12. Guzmán, H.R., Zhang, M.T.Z., Ratanabanangkoon, P., Shaw, P., Gardner, C.R., Chen, H., Moreau, J.P., Almarsson, O., Remenar, J.F., 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 96, 2686-2702.
13. Graeser, K.A., Patterson, J.E., Zeitler, J.A., Rades, T., 2010. The role of configurational entropy in amorphous systems. Pharmaceutics 2, 224-244.
14. Hancock, B.C., Parks, M., 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17 (4), 397-404.
15. Hoffman, J.D., 1958. Thermodynamic driving force in nucleation and growth processes. J. Chem. Phys. 29 (5), 1192-1193.
16. Hou, T., Wang, J., Zhang, W., Xu, X., 2007. ADME evaluation in drug discovery 7. Prediction of oral bioavailability by correlation and classification. J. Chem. Info. Model. 47 (1), 208-218.
17. Humphrey, M.J., 2005. Interface between drug discovery, ADME, and pharmaceutical development. Bull. Tech. Gattefossé 98, 65-74.
18. Jadhav, G.S., Vavia, P.R., 2008. Physicochemical, in silico and in vivo evaluation of a danazol-b-cyclodextrin complex. Int. J. Pharm. 352, 5-16.
19. Jain, N., Yalkowsky, S.H., 2001. Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J. Pharm. Sci. 90 (2), 234-252.
20. Jain, A.J., Yang, G., Yalkowsky, S.H., 2004. Estimation of melting points of organic compounds. Ind. Eng. Chem. Res. 43, 7618-7621.
21. Jain, A.J., Yalkowsky, S.H., 2006. Estimation of melting points of organic compounds-II. J. Pharm. Sci. 95 (12), 2562-2618.
22. Joback, K.G., Reid, R.C., 1987. Estimation of pure-component properties from groupcontributions. Chem. Eng. Comm. 57, 233-243.
23. Ku, S., 2006. An oral formulation decision tree based on biopharmaceutical classification system for first-in-man clinical trials. Bull. Tech. Gattefossée 98, 89-102.
24. Kuentz, M., 2008. Drug absorption modeling as a tool to define the strategy in clinical formulation development. AAPS J. 10 (3), 473-479.
25. Kuentz, M., 2012. Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discov. Today: Technol. 9 (2), e97-104.
26. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23 (1-3), 3-25.
27. Marsac, P.J., Konno, H., Taylor, L.S., 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm. Res. 23 (10), 2306-2316.
28. Mole, J., Box, K., Comer, J., Gravestock, T., Frake, E., 2009. Measuring drug supersaturation in the presence of additives and simulated GI fluids. AAPS Annual Meeting, Los Angeles.
29. Moore, M.D., Wildfong, P.L.D., 2011. Informatics calibration of a molecular descriptors database to predict solid dispersion potential of small molecule organic solids. Int. J. Pharm. 418, 217-226.
30. Murdande, S.B., Pikal, M.J., Shanker, R.M., Bogner, R.H., 2010a. Solubility advantage of amorphous pharmaceuticals: I. A Thermodynamic analysis. J. Pharm. Sci. 99 (3), 1254-1264.
31. Murdande, S.B., Pikal, M.J., Shanker, R.M., Bogner, R.H., 2010b. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm. Res. 27, 2704-2714.
32. Murdande, S.B., Pikal, M.J., Shanker, R.M., Bogner, R.H., 2011. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximal solubility advantage experimentally attainable and sustainable? J. Pharm. Sci. 100 (10), 4349-4356.
33. Newman, A., Knipp, G., Zografi, G., 2012. Assessing the performance of amorphous solid dispersions. J. Pharm. Sci. 101 (4), 1355-1377.
34. Nordström, F.L., Rasmuson, A.C., 2009. Prediction of solubility curves and melting properties of organic and pharmaceutical compounds. Eur. J. Pharm. Sci. 36, 330-344.
35. Porter, C.J., Pouton, C.W., Cuiné, J.F., Charman, W.N., 2008. Enhancing intestinal drug solubilisation using lipid-based drug delivery systems. Adv. Drug Deliv. Rev. 60, 673-691.
36. Rane, S.S., Anderson, B.D., 2008. What determines drug solubility in lipid vehicles: Is it predictable? Adv. Drug Del. Rev. 60, 638-656.
37. Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., Kopple, K.D., 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623.
38. Warren, D.B., Benameur, H., Porter, C.J., Pouton, C.W., 2010. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis of utility. J. Drug Target. 18 (10), 704-731.